MKI67 and adrenal cortex carcinoma: Patients aged 18 years or older with adrenocortical carcinoma and low to intermediate risk of recurrence (R0, stage I–III, and Ki67 ≤10%) were randomly assigned to adjuvant oral mitotane two or three times daily (the dose was adjusted by the local investigator with the target of reaching and maintaining plasma mitotane concentrations of 14–20 mg/L) for 2 years or surveillance alone.